For­mer Till­man Gern­gross Covid-19 an­ti­body start­up cuts costs and head­count again, one month af­ter re­brand

The com­pa­ny for­mer­ly known as Ada­gio has run in­to an­oth­er speed bump.

In­vivyd, which re­brand­ed last month in an at­tempt to shed its trou­bled rep­u­ta­tion, is find­ing it dif­fi­cult to chart its new path — the biotech an­nounced last Thurs­day that CFO and CBO Jane Hen­der­son will de­part, as well as chief com­mer­cial of­fi­cer Er­ic Kim­ble. In­vivyd is al­so lay­ing off staff, though did not spec­i­fy how many in a press re­lease or SEC fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER